| ID | 1527 | |
| PMID | 21310913 | |
| Year | 2011 | |
| Sequence | ALTVNTNIASLNTQRNLNNS SASLNTSLQRLSTGSRINSAKD DAAGLQIANRLTSQVNGL NVATKNANDGISLAQT AEGALQQSTNILQRMRDL SLQSANGSNSDSERTALN GEVKQLQKELDRISNTTTFGG RKLLDGSFGVASFQVG SAANEIISVGIDEMSAES LNGTYFKADGGGAVTAAT ASGTVDIAIGITGGSAVNV KVDMKGNETAEQAA AKIAAAVNDANVGI GAFSDGDTISY | |
| Name | Flagellin | |
| Length | 393 | |
| N-Terminal Modification | Free | |
| C-Terminal Modification | Free | |
| Linear/ Cyclic | Linear | |
| Chirality | L | |
| Chemical Modification | None | |
| Origin of Peptide | Flagellin was prepared from P. aeruginosa strain PA01 or PAK | |
| Nature of Peptide/Cargo | Topical flagellin enhanced innate immunity and protected injured corneas from C. albicans keratitis in a TLR5-dependent manner | |
| Mechanism | Flagellin was prepared from P. aeruginosa strain PA01 or PAK | |
| Cargo Sequence/Structure | None | |
| Name of cargo | Not applicable | |
| Assay | Fungal load determination, Myeloperoxidase(MPO) determination and Cytokine ELISA measurement | |
| Enhancer | PBS | |
| Properties of enhancer | Not mentioned | |
| Concentration | 500ng in 5µl of PBS | |
| Incubation time | 3 day post-infection | |
| Tissue permeability (value with units) | Clinical score: Flagellin treated-1-2/PBS-6-7, Fungal clearance: Flagellin-0/PBS-1.7CFU(1000) of C. albicans per cornea, Reduced cytokine production and PMN infiltration= MIP-2:Flagellin-0/PBS-5pg/µg protein; ELISA:Flagellin has less content of the protein under study than present in PBS; MPO activity per cornea: Flagellin has almost negligible activity as compared to PBS control. | |
| Tissue Sample | Eyes of wild type C57BL6 mice | |
| Ex vivo/In vivo/In vitro | in vitro | |
| STRUCTURE |
| |
| SMILES | N.A. | |